Updated: Apellis vows to be transparent about eye inflammation tied to Syfovre, but questions remain

Amber Tong

Senior Editor

Paul Schloesser

Associate Editor

Apellis Pharmaceuticals still can’t pinpoint exactly what’s behind the rare cases of eye inflammation that’s been reported in patients taking its geographic atrophy drug Syfovre …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Apellis vows to be transparent about eye inflammation tied to Syfovre, but questions remain

Amber Tong

Senior Editor

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Up­dat­ed: Apel­lis vows to be trans­par­ent about eye in­flam­ma­tion tied to Syfovre, but ques­tions re­main

Senior Editor

Associate Editor

Sign up to read this article for free.

Updated: Apellis vows to be transparent about eye inflammation tied to Syfovre, but questions remain